Lineage Cell Therapeutics (LCTX) Enterprise Value Growth (3y) (2013 - 2026)

Lineage Cell Therapeutics (LCTX) Enterprise Value Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Lineage Cell Therapeutics 251.15 Mn 188.44 Mn 1.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.82%
Dec 31, 2025 -1.59%
Sep 30, 2025 20.93%
Jun 30, 2025 15.96%
Mar 31, 2025 15.36%
Dec 31, 2024 9.39%
Sep 30, 2024 19.85%
Jun 30, 2024 17.02%
Mar 31, 2024 10.81%
Dec 31, 2023 9.71%
Sep 30, 2023 -3.03%
Jun 30, 2023 -29.10%
Mar 31, 2023 -20.60%
Dec 31, 2022 -22.27%
Sep 30, 2022 -21.99%
Jun 30, 2022 -58.83%
Mar 31, 2022 -41.47%
Dec 31, 2021 -22.67%
Sep 30, 2021 -42.25%
Jun 30, 2021 -40.13%